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Abstract
Background: Merkel cell polyomavirus (MCPyV) is a human polyomavirus that establishes a life-long harmless
infection in most individuals, with dermal fibroblasts believed to be the natural host cell. However, this virus is the
major cause of Merkel cell carcinoma (MCC), an aggressive skin cancer. Several MCPyV variants with polymorphism
in their promoter region have been isolated, but it is not known whether these differences affect the biological
properties of the virus.
Methods: Using transient transfection studies in human dermal fibroblasts and the MCC cell line MCC13, we
compared the transcription activity of the early and late promoters of the most commonly described non-coding
control region MCPyV variant and six other isolates containing specific mutation patterns.
Results: Both the early and late promoters were significantly stronger in human dermal fibroblasts compared with
MCC13 cells, and a different promoter strength between the MCPyV variants was observed. The expression of full-
length large T-antigen, a viral protein that regulates early and late promoter activity, inhibited early and late
promoter activities in both cell lines. Nonetheless, a truncated large T-antigen, which is expressed in virus-positive
MCCs, stimulated the activity of its cognate promoter.
Conclusion: The promoter activities of all MCPyV variants tested was stronger in human dermal fibroblasts, a cell
line that supports viral replication, than in MCC13 cells, which are not permissive for MCPyV. Truncated large T-
antigen, but not full-length large T-antigen stimulated viral promoter activity. Whether, the difference in promoter
strength and regulation by large T-antigen may affect the replication and tumorigenic properties of the virus
remains to be determined.
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Background
In 2008, a new human polyomavirus was isolated, which
rekindled the field of polyomavirus research [1]. This virus
was isolated from Merkel cell carcinoma (MCC), a rare but
aggressive skin cancer. Accordingly, this virus was named
Merkel cell polyomavirus (MCPyV). The original study
showed that 8 out of the 10 examined MCC samples con-
tained MCPyV DNA [1]. Numerous studies by different
groups worldwide have confirmed that approximately 80%
of MCCs are positive for this virus [2–5]. Because cell cul-
ture and transgenic mice studies have shown that MCPyV
has an oncogenic potential that can be attributed to its viral
proteins large T-antigen (LT) and small t-antigen (sT) ([6–
9]), and the association of the virus with MCC, MCPyV is
considered an etiological factor in MCC and is classified as
probably carcinogenic to humans [10]. Two hallmarks of
MCPyV-positive MCCs are the integration of the viral gen-
ome in the host chromosome and expression of a truncated
version of LT [5, 11]. Integration disrupts the late region so
that no infectious particles are generated in MCCs, while
the truncation of LT results in a non-DNA binding variant
that retains the ability to bind the tumor suppressor retino-
blastoma protein, but not p53 [12].
Serological studies demonstrated that seroprevalence against
MCPyV increases with age, and reaches up to ~80% in
healthy individuals [13–18]. Little is known about the route of
infection, transmission and the cell tropism of MCPyV. Der-
mal fibroblasts are a genuine host cell for MCPyV [19], and
the virus seems to persist in the skin [20–22]. However, PCR-
based analyses detected MCPyV DNA in other sites in the
body, both in healthy individuals and patients (Supplementary
Table S1), as well as in sewage water and environmental sur-
faces (Supplementary Table S2). The implication of MCPyV
in cancers other than MCC remains unknown, although viral
DNA, RNA and proteins can be detected in some cases of
other malignancies [23]. Sequence analysis of the MCPyV LT,
sT and VP1 genes of different virus isolates revealed genetic
variability, but the biological implications in the viral life cycle
and the development of MCC have not been studied.
Mutations in the non-coding control region (NCCR) of
human polyomaviruses like BKPyV, JCPyV, KIPyV, HPyV7,
HPyV9 and HPyV12 have an impact on the transcriptional
activity of the promoter, and may affect the virulence of the
virus [24–33]. Whether changes in the NCCR of MCPyV
have an effect on the promoter activity, and have pathogenic
consequences, has not been investigated. Here, we compare
the transcriptional activity of NCCR of different MCPyV var-
iants isolated from virus-positive MCC and non-MCC sam-
ples in a MCC cell line, and in human dermal fibroblasts.
Methods
Cells
The MCPyV-negative MCC13 cell line was kindly pro-
vided by Dr. Baki Akgül (University of Cologne, Germany)
and was grown in RPMI-1640 (Sigma Life Science, St.
Louis, MO. USA; cat. no. R8758) with 10% fetal bovine
serum (Gibco, Life Technologies Limited, Pailey, UK) in
the presence of 100 µg/ml streptomycin and 100 units/ml
penicillin. Immortalized human dermal fibroblasts fHDF/
TERT166 were purchased from Evercyte (Vienna, Austria)
and kept in DMEM/Ham’s F12 (1:1) (Biochrom, Berlin,
Germany; cat. no. F4815), 10% fetal bovine serum, 2mM
GlutaMaxTM-I (Giboco; cat. no. 35050–038) and 100 µg/
ml G418 (Santa Cruz Biotechnology, Dallas, TX, USA; cat.
no. sc-29,065). Cells were kept in a humidified CO2 incu-
bator at 37 °C.
Plasmids
The luciferase reporter plasmids with the consensus NCCR
MCPyV in early (pGL3-cons-E) or late (pGL3-cons-L)
orientation have been previously described [24]. The lucif-
erase reporter plasmids containing the NCCR of the vari-
ants 10b, 15a, 16b, HUN, MKL-1, MS-1 were generated by
GenScript (Piscataway, NJ, USA). Each NCCR was cloned
in both early (NCCR-E) and late (NCCR-L) orientation, re-
spectively. The luciferase plasmids with the NCCR contain-
ing the 25 bp duplication described by Hasida et al. [34]
was generated by site-directed mutagenesis using the plas-
mid pGL3-cons-E (pGL3-cons-L, respectively) containing





expression vector pcDNA3.1(+) was purchased from Invi-
trogen (ThermoFisher Scientific, Oslo, Norway). The
MCPyV expression vectors for full-length and truncated LT
have been previously described [35], and all plasmids were
verified by sequencing. Expression of full-length and trun-
cated LT was confirmed by western blotting using antibody
CM2B4 from Santa Cruz Biotechnology (Dallas, TX, USA;
cat. no. sc-136,172; results not shown).
Transfection and luciferase assay
Cells were seeded out in 12-well culture plates. At the
time of transfection, the cells were approximately 70%
confluent, with a total of 1 µg luciferase reporter plasmid
DNA used per well and polyethylenimine (PEI linear
MW25000; transfection grade, cat. no. 23966–1, Poly-
sciences, Warrington, PA, USA). DNA was mixed with
150 mM NaCl, and a mixture of PEI:150 mM NaCl was
then added to the DNA. The ratio DNA:PEI used was 1:
2. This mixture was incubated for 15 min at room
temperature, and then carefully added to the cells. The
medium containing the transfection mixture was re-
placed 4 h later. Cells were harvested 24 h after transfec-
tion in a 100 µl Tropix lysis buffer per well with 0.5 mM
DTT freshly added. Cells were centrifuged for 3 min at
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12,000 g, and the supernatant was then transferred to a
fresh tube. As previously described, 20 µl of supernatant
was used in the luciferase assay [35]. Each experiment
was repeated at least 3 times, with three independent
parallels for each experiment. Luciferase values for each
sample were corrected for total protein concentration as
determined with the MN protein quantification assay
described by the producer (Macherey-Nagel GmbH,
Düren, Germany). We corrected luciferase values by
measuring the protein concentration in the correspond-
ing sample rather than co-transfection with a Renilla re-
porter plasmid to avoid promoter interference between
the MCPyV NCCR directing expression of the firefly lu-
ciferase gene and a promoter controlling expression of
the Renilla luciferase gene. In addition, many of our
transfection studies include co-transfection with LT ex-
pression plasmids, containing the strong competing
CMV promoter. Moreover, LT of polyomaviruses have
shown activate many promoters, including the SV40
promoter or the herpes simplex virus thymidine kinase
promoter [36], which are commonly used in Renilla re-
porter plasmids.
Statistics
A two-tailed Student’s t-test was used to determine stat-
istical differences between the MCPyV promoter
variants.
Results
The known MCPyV NCCRs can be classified in six different
groups
A comparison of all available complete NCCR sequences
of MCPyV variants revealed a predominant sequence,
which is hereafter referred to as the consensus sequence
shown in Fig. 1. Based on this consensus sequence, we
classified the different NCCR variants in seven groups
(Fig. 1 and Table 1). Group 1 contains the MCPyV
strains with a consensus or quasi consensus (i.e. one or
few point mutations). Group 2 contains NCCR variants
with an insertion of the AAC or AACTC sequence at
nucleotide 369 (numbering according to the consensus
sequence). Group 3 NCCR has an insertion of the
TCAAT sequence at nucleotide 372, while group 4 has
deletion of the CCTTAGAT sequence (nucleotides 105–
112). Group 5 has both an insertion (ACAA or ACAAC
at nucleotide 372) and a deletion of nucleotides 381–387
(AACAAGG). The NCCR in group 6 has three inser-
tions: CAAC after nucleotide 373, T after nucleotide 379
and AA after nucleotide 383. Lastly, group 7 variants
have a 25 bp duplication.
The biological source of each NCCR variant is given in
Table 1 and Supplementary Table S1. Consensus NCCRs
are found in strains present in non-diseased and diseases
tissue/individuals. Likewise, NCCR variants circulate in
healthy individuals and patients. MCPyV variants with
consensus and mutated NCCRs have been isolated from
Fig. 1 The MCPyV NCCR region and the different variants. The top panel of the figure shows the consensus nucleotide sequence based on variant
R17b (GenBank accession number NC_010277), with the first nucleotide in the NCCR numbered 1 and the last numbered 464. The putative LT binding
sequences (GRGGC) are shown in boxes. The bottom part shows a schematic presentation of the NCCR, with the thick vertical lines representing
putative LT binding motifs [37]. The early region is indicated on the left and the late region on the right. The different groups of NCCR variants and
their major mutations are indicated. The larger insertions (ins) and deletions (Δ) are given, whereas point mutations are not shown
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sewage water (see Table 1 for references). The mutations
for each NCCR variant are presented in Supplementary
Table S3.
Basal early and late promoter activities in MCC13 and
human dermal fibroblasts cells
Because MCPyV-positive Merkel cell carcinoma derives
from virus-transformed Merkel cells [1], and human der-
mal fibroblasts (HDF) have been shown to be permissive
for this virus and considered as genuine host cells for
the virus [19], we examined the basal early and late pro-
moter activity of MCPyV variants in these two cell lines.
To study the effect of mutations in the NCCR on basal
early and late promoter activity, one NCCR variant was
selected from each group, with the exception of group 1,
in which both the consensus sequence and a variant with
few point mutations were tested (Table 1). The NCCRs
were cloned in both orientations, and the basal early and
late promoter activities were monitored in the MCPyV-
negative MCC cell line MCC13, in addition to primary
dermal fibroblasts.
Comparing the relative basal early and late promoter
activities showed that both promoters were stronger in
HDF cells compared to MCC13 cells (Supplementary
Fig. S1). The cons-E promoter was ~ 4-fold stronger,
while the cons-L was ~3x stronger. The difference is
probably even more because the transfection efficiency
in MCC13 cells was approximately 60–70%, whereas in
HDF the transfection efficiency was estimated to be ~
30% (results not shown). Comparing the cons-E and
cons-L in MCC13 revealed that the late promoter was
approximately 8x stronger than the early promoter. The
cons-L was approximately 6x stronger in HDF than in
MCC13 cells (Supplementary Fig. S1).
Effect of large T-antigen on early and late promoter
activities
Large T-antigen of polyomaviruses has been shown to
affect the early and late promoter activities. To examine
the effect of LT on the MCPyV promoters, we co-
transfected MCC13 cells with 1 µg luciferase reporter
plasmid with the cons-E promoter, with increasing
amounts (0, 100, 200, 400, 500, 800 and 1000 ng) of
empty pcDNA3.1 vector or LT expression vector. All
concentrations reduced cons-E promoter activity (results
not shown), but high concentrations (800 and 1000 ng)
of empty vector almost completely inhibited MCPyV
promoter activity. Both the empty vector and the LT ex-
pression plasmid contain the strong CMV immediate
early promoter. We found this promoter to be > 5-fold
stronger than the cons-E promoter in MCC13 cells and
~40x stronger in HDF cells (Supplementary Fig. S2). We
decided to test the effect of two different concentrations
(100 and 500 ng) of LT expression plasmid on all variant
NCCRs. Both concentrations of LT expression plasmid
(100 ng and 500 ng) significantly reduced the activity of
all early promoters in MCC13 cells (Fig. 3a and b). A
similar effect was observed for the late promoters, with
the exception of the MS1 and HUN promoters, which
were induced when cells were co-transfected with 500
ng of LT expression plasmid (Fig. 3c and d).
We also examined the effect of LT on the MCPyV
promoters in HDF cells. Both concentrations of LT ex-
pression plasmid (100 ng and 500 ng) significantly re-
pressed the early promoter activity (Fig. 4a and b) and
the late promoter activity (Fig. 4c and d) of all variant
NCCRs tested. However, a somewhat stronger inhibition
was observed with the lowest concentration of LT ex-
pression plasmid, while at higher concentrations pro-
moter interference becomes more pronounced.
MCPyV-positive MCCs contain integrated viral DNA,
and are further characterized by the expression of a C-
terminal truncated LT [Feng, 2008]. Thus, we examined
the effect of truncated LT on the early and late pro-
moter. Of the seven different strains examined in this
work, only MKL-1 and MS-1 have been isolated from
MCC [40, 41], whereas the HUN strain was obtained
from a metastatic cervical lymph node from a Hungarian
patient, though no further information is available [39].
We therefore decided to test the impact of MKL-1 (MS-
1, respectively) truncated LT on their cognate promoter.
The luciferase reporter plasmids with the early or late
Table 1 MCPyV NCCR variants examined in this study
Group NCCR variant Referred to in this paper Source Reference
1 R17b cons-E and cons-L healthy skin [20]
MKL-1 MKL1-E and MKL1-L MCC [38]
2 MS-1 MS1-E and MS1-L MCC [1]
3 7673/2011/HUN HUN-E and HUN-L metastatic cervical lymph node [39]
4 R15a 15a-E and 15a-L healthy skin [20]
5 R10b 10b-E and 10b-L healthy skin [20]
6 R16b 16b-E and 16b-L healthy skin [20]
7 Subtype I Ins25-E and ins25-L healthy skin [34]
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promoter of MKL-1 (MS-1, respectively) were co-
transfected with an expression plasmid for MKL-1 LT
(MS-1 LT, respectively) in MCC13 and in HDF cells,
and the promoter activity was monitored. Truncated
MKL-1 LT stimulated the MKL-1 early and late pro-
moter activities in both MCC13 and HDF cells (Fig. 5a
and b). The only exception was when 500 ng of MKL-1
LT expression plasmid was used, with a significant in-
hibition of the early promoter observed in HDF cells
(Fig. 5b). Truncated MS-1 LT also stimulated the early
and late MS-1 promoter in MCC13 cells and the late
promoter in HDF cells (Fig. 5a and b), but inhibited the
early promoter in HDF cells (Fig. 5b). With 100 ng of
truncated MS-1 LT expression plasmid, a reduction in
Fig. 2 Relative promoter activities of different MCPyV NCCR variants in MCC13 and human dermal fibroblast cells. Cells in 12-well plates were
transiently transfected with 1 μg luciferase reporter plasmid containing the early promoter of MCPyV. Luciferase activity was corrected for total
protein concentration of the sample, and the corrected value for the early consensus (late consensus, respectively) promoter was arbitrarily set as
100%. Each bar represents the average of three independent parallels + standard deviation. A representative result is shown, and each promoter
was tested at least three times in independent experiments with similar results; *p < 0.05, **p < 0.01
Fig. 3 Effect of MCPyV LT on early and late promoter activity in MCC13 cells. Cells were co-transfected with 1 μg luciferase reporter plasmid with
the early promoter of the MCPyV variants and 100 ng of empty pcDNA3.1 vector (EV) or LT expression plasmid (a and c), or with 500 ng of empty
vector or LT expression plasmid (b and d). The effect on the early MCPyV promoters is depicted in A and B, while the effect on the late
promoters is shown in C and D. Luciferase activity was corrected for protein concentration in each sample, and the activity in the presence of an
empty vector was arbitrary set as 100%. Each bar represents the average of three independent parallels + SD. Similar results were obtained in an
independent experiment; *p < 0.05; **p < 0.01
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promoter activity of 15–24% compared to the control
was observed. However, this decrease was not significant
(p-values between 0.0553 and 0.0632 in the different
experiments).
Discussion
MCPyV has a seroprevalence of approximately 80% in
the healthy, adult population [13–18]. MCPyV is chron-
ically shed from healthy skin [20], but can also cause an
aggressive skin cancer known as Merkel cell carcinoma
[1]. Several MCPyV variants have been described with
mutations in their NCCR (Supplementary Table S3).
These variants have been isolated from both healthy tis-
sue and tumors, but so far, no typical strain seems to be
associated with MCC (Supplementary Table S3). The
mutations described in the known MCPyV variants
could be classified in seven groups with group 1 contain-
ing the most common NCCR, which was referred to as
the consensus sequence in our study and variants with
one or a few point mutations. Groups 2–7 contain inser-
tions and/or deletions in their NCCR. Significant differ-
ences in basal early and late promoter activities in HDF
and MCC13 cells were observed. The basal early-, as
well as late promoter activity, of all variants tested was
higher in HDF cells than in MCC13 cells despite a lower
transfection efficiency (Fig. 6). This may indicate that
the MCPyV promoter is more adapted to the former cell
type. HDF have been suggested as natural host cells for
the virus and are permissive for the virus, while the in-
fection of Merkel cells and the subsequent transform-
ation of these cells could be seen as an accidental and
unfortunate event [19].
Co-transfection with a 100 ng of full-length LT ex-
pression plasmid resulted in reduced early and late pro-
moter activity of all variants in both MCC13 and HDF
cells (Fig. 6). However, 500 ng of LT expression plasmid
reduced early and late promoter activities in HDF and
early promoter activity in MCC13 cells, but had only a
slight or no effect, but significantly stimulated the HUN
and MS1 (a 20 and 40% increase, respectively) late pro-
moters. Kwun et al. found that MCPyV LT repressed
early and late promoter activity of MCPyV isolate
MCC339 in HEK293 cells, but they did not examine
the effect of LT in MCC13 or HDF cells [42]. Yet, in
another study by Ajuh and co-workers, the authors
showed that LT trans-activated the MCPyV R17b (=
consensus) early and late promoter in HEK293T cells
[29]. The discrepancy between their results and the
findings by Kwun et al. and us can be explained by the
use of different LT. HEK293T cells express both SV40
LT and sT, but not MCPyV LT [29]. Moreover, the
possible contribution of sT in the trans-activation of
the early and late MCPyV promoters in these cells was
not investigated. Furthermore, Ajuh et al. studied the
Fig. 4 Effect of MCPyV LT on early and late promoter activity in HDF cells. For details, see legend of Fig. 3
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effect of LT using a bidirectional reporter vector,
thereby allowing for the simultaneous monitoring of
the early and late promoter activity, whereas both we
and Kwun et al. examined early and late promoter inde-
pendently, which better reflects the situation in infected
cells. Indeed, during the polyomavirus life cycle, early
and late promoters are activated in a time-dependent
fashion. The early promoter is active early during infec-
tion, and the expression of LT will result in the autore-
pression of the early promoter and a switch to
activation of the late promoter [43]. Another experi-
mental difference was that we measured promoter ac-
tivities 24 h after transfection, whereas Ajuh and
colleagues determined promoter activities 48 h post
transfection. Lastly, we used dose-dependent studies
with LT, while Ajuh and co-workers used cells consti-
tutively expressing LT. The authors also examined the
effect of MCPyV LT on early and late promoter activity
of the consensus MCPyV variant and MCVw156 (con-
sensus with one substitution and one deletion; Supple-
mentary Table S3) in HEK293MCT cells (i.e. HEK293
cells stably expressing MCPyV LT). While early pro-
moters of both MCPyV variants were significantly stim-
ulated by MCPyV LT, no effect was observed on their
late promoter. A possible explanation for the different
effects of SV40 LT and MCPyV LT on the MCPyV late
promoter was not provided by the authors.
Because the viral genome in MCC expresses a trun-
cated LT, we examined the effect of truncated LT on its
cognate promoter. Truncated MKL-1 (MS-1, respect-
ively) LT stimulated its cognate early and late promoter
in MCC13 cells, whereas stimulation was only observed
for the late promoter in HDF cells. In these cells, trun-
cated MKL-1 and MS-1 LT inhibited the corresponding
early promoter. The reason for the cell-specific effect of
truncated LT on the MCPyV promoter is not known,
but MCPyV LT has been shown to interact with several
cellular factors [42]. Different interaction partners in dis-
tinct cell types may determine the effect of LT on the
MCPyV promoter activity. The fact that truncated LT
stimulates their cognate early promoter in MCC13 may
indicate a positive feedback loop that results in higher
expression levels of the early proteins, including the
oncoproteins sT and LT. Our preliminary results shows
that also truncated MKL-2 LT (which differs from HUN
truncated LT by replacement of Ala20 into Ser and
Ser263 into Phe, and the lack of the three C-terminal
amino acids Ser-Arg-Lys) was able to stimulate the
HUN-E promoter approximately 2-fold in MCC13 cells
(our unpublished results), suggesting that it may be a
Fig. 5 The effect of truncated LT on its cognate promoter in MCC13 and HDF cells. (A) MCC13 cells were co-transfected with the luciferase
reporter plasmid containing the early MKL-1 (MS-1, respectively) promoter, and either empty vector (EV), full-length LT, or truncated LT (tLT)
encoded by the MKL-1 (MS-1, respectively) MCPyV variant; (b) as (a,) but luciferase reporter plasmids containing the late promoter of MKL-1 or
MS-1 were used. Cells were also co-transfected with the reporter plasmid containing the early or late consensus promoter and empty vector or
LT expression plasmid. (c) and (d) As (a) and (b), respectively, but transfections were performed in HDF cells. Luciferase activity was corrected for
the protein concentration in each sample, with the activity in the presence of the empty vector arbitrarily set as 100%. Each bar represents the
average of three independent + SD. Similar results were obtained in two additional experiment; *p < 0.05, **p < 0.01
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common feature of truncated LT to autostimulate its ex-
pression. This positive autoregulation of LT and sT could
be potentially important for tumorigenesis. Since full-
length LT had an inhibitory effect on the promoters, it
would be interested to test whether full-length LT reverses
the activity of truncated LT. However, to be of biological
relevance, both full-length and truncated LT must be co-
expressed in MCPyV infected cells. To our best know-
ledge, only truncated LT is expressed in virus-positive
MCCs. We are aware of only two studies were co-
expression of full-length and truncated LT was observed.
One case of non small cell lung cancer (a squamous cell
carcinoma) with both episomal and integrated viral DNA
and both full-length and truncated LT protein was de-
scribed by Hashida and co-workers [44]. In another study,
mRNAs for truncated and full- length LT were confirmed
by highly sensitive qRT-PCR in two cases of chronic
lymphocytic leukemia, but expression of truncated and
full-length LT at protein level was not investigated [45].
The genome copy per chronic lymphocytic leukemia cell
was 3 to 4 logs lower than MCPyV-positive MCCs, sug-
gesting that very low levels of LT/truncated LT are
present in these cells. It remains to be determined whether
such low levels have any biological relevance for the viral
life cycle or tumorigenesis. Because integration of the
MCPyV genome interrupts the late region, no late pro-
teins are expressed and no viral particles are produced.
The biological implication of enhanced late promoter ac-
tivity by truncated LT in MCC remains elusive.
Our transient transfection studies showed that the
MCPyV NCCR variants possess different promoter activ-
ity, and can lead to different expression levels of the viral
proteins. This has been confirmed by in situ studies. The
CVG-1 and MKL-1 MCC cell lines both contain seven
copies of the integrated virus genome per diploid cell [46].
The CVG-1 cell line contains the consensus NCCR se-
quence, while MKL-1 contains one single point mutation
(T52C; Supplementary Table S2). Quantitative real-time
PCR demonstrated that the total LT and sT mRNA ex-
pression levels were approximately 2.5 times higher in
CVG-1 cells compared to MKL-1 cells, thus indicating
that the former promoter is 2.5x stronger than the latter.
Our transient transfection study in MCC13 cells con-
firmed that the MKL-1 early promoter was weaker than
the consensus early promoter (Fig. 2). The expression
levels of early proteins in MCC not only depend on the
strength of the early promoter, but the number of inte-
grated viral genomes and the integration site (hetero- ver-
sus euchromatin) may also influence the promoter
strength. Velásquez et al. determined that MKL-2 and
Fig. 6 Heatmap showing the relative promoter activities of eight MCPyV NCCR variants in MCC13 and human dermal fibroblasts (HDF) in the
absence and presence of large T antigen (LT). The activity of the consensus NCCR (cons) was arbitrary set as 100 and the activities of the other
promoters were related to this
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MS-1 MCC cells contain two and four genome copies per
diploid cells, respectively [46]. The LT transcript levels
were approximately 2-fold higher in MS-1 cells compared
to the MKL-2 cells, while the ST mRNA levels were 4x
higher in MS-1 cells than in MKL-2 cells. The complete
NCCR sequence of the MKL-2 variant has not been deter-
mined, but the 240 nucleotides downstream of the LT
start codon are identical with the consensus sequence.
The MCPyV NCCR contains a plethora of putative tran-
scription factor binding motifs (see Supplementary Fig. 3
and Supplementary Table S4), but the binding of the corre-
sponding transcription factor has not been confirmed.
Whether the mutations found in these sites in the NCCR
variants we investigated abolished binding of the transcrip-
tion factor, has not been tested. The 25 bp insertion gener-
ates putative binding motifs for the transcription factors
FOXO3a, SRY, Elk-1 and p300, but their possible role in
regulating the promoter activity remains to be investigated.
Conclusions
Our study shows that the promoters of different MCPyV
isolates possess unlike transcriptional activity, and that full-
length LT and MCC-associated truncated LT have a dis-
tinct impact on the promoter. Whether these differences in
promoter activity contribute to the replication and trans-
formation properties of the virus remains to be determined.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12985-020-01317-x.
Additional file 1 Supplementary Fig. S1. Early and late promoter
activity of seven MCPyV NCCR variants in MCC13 and human dermal
fibroblasts. Supplementary Fig. S2. Relative promoter activity of the
immediately early cytomegalovirus and the consensus early MCPyV
promoter in MCC13 and human dermal fibroblasts. Supplementary Fig.
S3. Putative transcription factor binding sites in the consensus MCPyV
NCCR. Supplementary Table S1. Detection of MCPyV in benign and
diseased human tissues other than Merkel cell carcinoma.
Supplementary Table S2. MCPyV isolated in sewage water and
environmental surfaces. Supplementary Table S3. MCPyV NCCR
variants and mutations compared to the consensus sequence.
Supplementary Table S4. Putative transcription factor binding sites in
the consensus MCPyV NCCR.
Abbreviations
HDF: Human dermal fibroblasts; LT: Large T antigen; MCC: Merkel cell
carcinoma; MCPyV: Merkel cell polyomavirus; NCCR: Non-coding control
region; sT: Small T antigen; tLT: Truncated large T antigen
Acknowledgments
The authors wish to thank Dr. Baki Akgül from the University of Cologne,
Germany for providing MCC13 cells.
Authors’ contributions
Conceptualization, U.M. and B.E.; experiments, I.A., K.R., and U.M.; validation,
B.E., U.M.; writing—original draft preparation, U.M. and B.E.; writing—review
and editing, I.A., K. R, B.S., E. B, and U.M.; supervision, U.M. and B.S.; project
administration, U.M.; funding acquisition, U.M. and B.S. The author (s) read
and approved the final manuscript.
Funding
This research was funded by “Helse-Nord Forskningsmidler” project 23226.
The APC was funded by the UiT, The Arctic University of Norway.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.





The authors declare that they have no competing interests.
Author details
1Molecular Inflammation Research Group, Department of Medical Biology,
Faculty of Health Sciences, University of Tromsø, The Arctic University of
Norway, Tromsø, Norway. 2Present address: Tumor Biology Research Group,
Department of Medical Biology, Faculty of Health Sciences, University of
Tromsø, The Arctic University of Norway, Tromsø, Norway. 3Division 12
Measles, Mumps, Rubella and Viruses Affecting Immunocompromised
Patients, Robert Koch Institute, Berlin, Germany.
Received: 19 December 2019 Accepted: 10 March 2020
References
1. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus
in human Merkel cell carcinoma. Science. 2008;319:1096–100. https://doi.
org/10.1126/science.1152586.
2. Kassem A, Schöpflin A, Diaz C, Weyers W, Stickler E, Werner M, Zur HA.
Frequent detection of Merkel cell polyomavirus in human Merkel cell
carcinomas and identification of a unique deletion in the VP1 gene. Cancer
Res. 2008;68:5009–13. https://doi.org/10.1158/0008-5472.CAN-08-0949.
3. Foulongne V, Kluger N, Dereure O, Brieu N, Guillot B, Segondy M. Merkel
cell polyomavirus and Merkel cell carcinoma. France Emerg Dis. 2008;14:
1491–3. https://doi.org/10.3201/eid1409.080651.
4. Becker JC, Houben R, Ugurel S, Trefzer U, Pföhler C, Schrama D. MC polyomavirus
is frequently present in Merkel cell carcinoma of European patients. J Invest
Dermatol. 2009;129:248–50. https://doi.org/10.1038/jid.2008.198.
5. Van Ghelue M, Moens U. Merkel cell polyomaviurs: a causal factor in Merkel cell
carcinoma. In: La Porta CAM, editor. Skin cancers-risk factors, prevention and
therapy. Croatiia: IntechOpen; 2011. p. 109–42. https://doi.org/10.5772/25675.
6. Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel
cell polyomavirus. Curr Opin Virol. 2015;11:38–43. https://doi.org/10.1016/j.
coviro.2015.01.009.
7. Shuda M, Guastafierro A, Geng X, Shuda Y, Ostrowski SM, Lukianov S,
Jenkins FJ, Honda K, Maricich SM, Moore PS, Chang Y. Merkel cell
Polyomavirus small T antigen induces Cancer and embryonic Merkel cell
proliferation in a transgenic mouse model. PLoS One. e01423292015;10.
https://doi.org/10.1371/journal.pone.0142329.
8. Verhaegen ME, Mangelberger D, Harms PW, Vozheiko TD, Weick JW, Wilbert DM,
Saunders TL, Ermilov AN, Bichakjian CK, Johnson TM, Imperiale MJ, Dlugosz AA.
Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest
Dermatol. 2015;135:1415–24. https://doi.org/10.1038/jid.2014.446.
9. Spurgeon ME, Cheng J, Bronson RT, Lambert PF, DeCaprio, J.A. Tumorigenic
activity of merkel cell polyomavirus T antigens expressed in the stratified
epithelium of mice. Cancer Res 2015;75:1068–1079. doi: https://doi.org/10.
1158/0008-5472.CAN-14-2425.
10. Bouvard V, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Benbrahim-
Tallaa L, Guha N, Straif K. Carcinogenicity of malaria and of some
polyomaviruses. Lancet Oncol. 2012;13:339–40.
11. Stakaityte G, Wood JJ, Knight LM, Abdul-Sada H, Adzahar NS, Nwogu N,
Macdonald A, Whitehouse A. Merkel cell polyomavirus: molecular insights
into the most recently discovered human tumour virus. Cancers. 2014;6:
1267–97. https://doi.org/10.3390/cancers6031267.
12. Borchert S, Czech-Sioli M, Neumann F, Schmidt C, Wimmer P, Dobner T,
Grundhoff A, Fischer N. High-affinity Rb binding, p53 inhibition, subcellular
Abdulsalam et al. Virology Journal           (2020) 17:54 Page 9 of 10
localization, and transformation by wild-type or tumor-derived shortened
Merkel cell polyomavirus large T antigens. J Virol. 2014;88:3144–60. https://
doi.org/10.1128/JVI.02916-13.
13. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, Fulp W,
Ajidahun A, Rivanera D. Age-specific seroprevalence of Merkel cell
polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol. 2011;18:1737–43.
https://doi.org/10.1128/CVI.05175-11.
14. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human
polyomaviruses. PLoS Pathog. 2009;5:e1000363. https://doi.org/10.1371/
journal.ppat.1000363.
15. Zhang C, Liu F, He Z, Deng Q, Pan Y, Liu Y, Zhang C, Ning T, Guo C, Liang
Y, Xu R, Zhang L, Cai H, Ke Y. Seroprevalence of Merkel cell polyomavirus in
the general rural population of Anyang. China PLoS One. 2014;9:e106430.
https://doi.org/10.1371/journal.pone.0106430.
16. Martel-Jantin C, Pedergnana V, Nicol JT, Leblond V, Tregouet DA, Tortevoye P,
Plancoulaine S, Coursaget P, Touze A, Abel L. Gessain, A. Merkel cell polyomavirus
infection occurs during early childhood and is transmitted between siblings. J
Clin Virol 2013;58:288–291. doi: https://doi.org/10.1016/j.jcv.2013.06.004.
17. Nicol JT, Robinot R, Carpentier A, Carandina G, Mazzoni E, Tognon M, Touze A,
Coursaget P. Age-specific seroprevalences of merkel cell polyomavirus, human
polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus.
Clin Vaccine Immunol. 2013;20:363–8. https://doi.org/10.1128/CVI.00438-12.
18. Kamminga S. E van der Meijden E, Feltkamp MCW. Zaaijer HL Seroprevalence
of fourteen human polyomaviruses determined in blood donors PLoS One.
2018;13:e0206273. https://doi.org/10.1371/journal.pone.0206273.
19. Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, Xu X,
Buck CB, You J. Identifying the target cells and mechanisms of Merkel cell
Polyomavirus infection. Cell Host Microbe. 2016;19:775–87. https://doi.org/
10.1016/j.chom.2016.04.024.
20. RM RS, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell
polyomavirus and two previously unknown polyomaviruses are chronically
shed from human skin. Cell Host Microbe. 2010;7:509–15. https://doi.org/10.
1016/j.chom.2010.05.006.
21. Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, Pariente
K, Segondy M, Burguiere A, Manuguerra JC, Caro V, Eloit M. Human skin
microbiota: high diversity of DNA viruses identified on the human skin by
high throughput sequencing. PLoS One. 2012;7:e38499. https://doi.org/10.
1371/journal.pone.0038499.
22. Hashida Y, Kamioka M, Tanaka M, Hosokawa S, Murakami M, Nakajima K,
Kikuchi H, Fujieda M, Sano S, Daibata M. Ecology of Merkel cell
Polyomavirus in healthy skin among individuals in an Asian cohort. J Infect
Dis. 2016;213:1708–16. https://doi.org/10.1093/infdis/jiw040.
23. Csoboz B, Rasheed K, Sveinbjørnsson U. Moens U. Merkel cell polyomavirus
and non-Merkel cell carcinomas: guilty or circumstantial evidence? APMIS.
2020; [Online ahead of print]. https://doi.org/10.1111/apm.13019.
24. Moens U, Van Ghelue M, Ludvigsen M, Korup-Schulz S, Ehlers B. The early
and late promoters of BKPyV, MCPyV, TSPyV, and HPyV12 are among the
strongest of all known human polyomaviruses in 10 different cell lines. J
Gen Virol. 2015;96:2293–303. https://doi.org/10.1099/vir.0.000181.
25. Moens U, Song X, Van Ghelue M, Lednicky JA, Ehlers, B. A Role of Sp1
Binding Motifs in Basal and Large T-Antigen-Induced Promoter Activities of
Human Polyomavirus HPyV9 and Its Variant UF-1. Int J Mol Sci. 2017;18:pii:
E2414. doi: https://doi.org/10.3390/ijms18112414.
26. Song X, Van Ghelue M, Ludvigsen M, Nordbo SA, Ehlers B, Moens U.
Characterization of the non-coding control region of polyomavirus KI
isolated from nasopharyngeal samples from patients with respiratory
symptoms or infection and from blood from healthy blood donors in
Norway. J Gen Virol. 2016;97:1647–57. https://doi.org/10.1099/jgv.0.000473.
27. Gosert R, Rinaldo CH, Funk GA, Egli A, Ramos E, Drachenberg CB, Hirsch HH.
Polyomavirus BK with rearranged noncoding control region emerge in vivo
in renal transplant patients and increase viral replication and cytopathology.
J Exp Med. 2008;205:841–52. https://doi.org/10.1084/jem.20072097.
28. Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding
control regions found in progressive multifocal leukoencephalopathy
patient samples increase virus early gene expression and replication rate. J
Virol. 2010;84:10448–56. https://doi.org/10.1128/JVI.00614-10.
29. Ajuh ET, Wu Z, Kraus E, Weissbach FH, Bethge T, Gosert R, Fisher N, Hirsch
HH. Novel human polyomavirus noncoding control region differ in
bidirectional gene expression according to host cell, large T-antigen
expression, and clinically occurring rearrangements. J Virol. 2018;92:e02231–
17. https://doi.org/10.1128/JVI.02231-17.
30. Barcena-Panero A, Echevarria JE, Van Ghelue M, Fedele G, Royuela E, Gerits
N, Moens U. BK polyomavirus with archetypal and rearranged non-coding
control regions is present in cerebrospinal fluids from patients with
neurological complications. J Gen Virol. 2012;93:1780–94. https://doi.org/10.
1099/vir.0.042143-0.
31. Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO,
Tritsmans L, Stuyver LJ. JC virus quasispecies analysis reveals a complex viral
population underlying progressive multifocal leukoencephalopathy and
supports viral dissemination via the hematogenous route. J Virol. 2015;89:
1340–7. https://doi.org/10.1128/JVI.02565-14.
32. L'Honneur AS, Leh H, Laurent-Tchenio F, Hazan U, Rozenberg F, Bury-Mone
S. Exploring the role of NCCR variation on JC polyomavirus expression from
dual reporter minicircles. PLoS One. 2018;13:e0199171. https://doi.org/10.
1371/journal.pone.0199171.
33. Takahashi K, Sekizuka T, Fukumoto H, Nakamichi K, Suzuki T, Sato Y,
Hasegawa H, Kuroda M, Katano H. Deep-Sequence Identification and Role in
Virus Replication of a JC Virus Quasispecies in Patients with Progressive
Multifocal Leukoencephalopathy. J Virol. 2016;91:pii: e01335–e01316. doi:
https://doi.org/10.1128/JVI.01335-16.
34. Hashida Y, Higuchi T, Matsui K, Shibata Y, Nakajima K, Sano S, Daibata M.
Genetic variability of the noncoding control region of cutaneous Merkel cell
Polyomavirus: identification of geographically related genotypes. J Infect
Dis. 2018;217:1601–11. https://doi.org/10.1093/infdis/jiy070.
35. Rasheed K, Abdulsalam I, Fismen S, Grimstad Ø, Sveinbjornsson B, Moens U.
CCL17/TARC and CCR4 expression in Merkel cell carcinoma. Oncotarget.
2018;9:31432–47. https://doi.org/10.18632/oncotarget.25836.
36. Pannuti A, Pascucci A, La Mantia G, Fisher-Fantuzzi L, Vesco C, Lania L.
Trans-activation of cellular and viral promoters by a transforming
nonkaryophilic simian virus 40 large T antigen. J Virol. 1987;61:1296–9.
37. Harrison C, Jiang T, Banerjee P, Meinke G, D'Abramo CM, Schaffhausen B,
Bohm A. Polyomavirus large T antigen binds symmetrical repeats at the
viral origin in an asymmetrical manner. J Virol. 2013;87:13751–9. https://doi.
org/10.1128/JVI.01740-13.
38. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, Chang Y. T
antigen mutations are a human tumor-specific signature for Merkel cell
polyomavirus. Proc Natl Acad Sci U S A. 2008;105:16272–7. https://doi.org/
10.1073/pnas.0806526105.
39. Horvath KB, Pankovics P, Battyani Z, Kalman E, Reuter G. A probable etiological
role of Merkel cell polyomavirus in the development of Merkel cell carcinoma.
Orv Hetil. 2013;154:102–12. https://doi.org/10.1556/OH.2013.29525.
40. Rosen ST, Gould VE, Salwen HR, Herst CV, Le Beau MM, Lee I, Bauer K,
Marder RJ, Andersen R, Kies MS, et al. Establishment and characterization of
a neuroendocrine skin carcinoma cell line. Lab Investig. 1987;56:302–12.
41. Guastafierro A, Feng H, Thant M, Kirkwood JM, Chang Y, Moore PS, Shuda M.
Characterization of an early passage Merkel cell polyomavirus-positive Merkel
cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol
Methods. 2013;187:6–14. https://doi.org/10.1016/j.jviromet.2012.10.001.
42. Kwun HJ, Chang Y, Moore PS. Protein-mediated viral latency is a novel
mechanism for Merkel cell polyomavirus persistence. Proc Natl Acad Sci U S
A. 2017;114:e4040–7. https://doi.org/10.1073/pnas.1703879114.
43. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S,
Lauber C. Biology, evolution, and medical importance of polyomaviruses: an
update. Infect Genet Evol. 2017;54:18–38. https://doi.org/10.1016/j.meegid.
2017.06.011.
44. Hashida Y, Imajoh M, Nemoto Y, Kamioka M, Taniguchi A, Taguchi T, Kume
M, Orihashi K, Daibata M. Detection of Merkel cell polyomavirus with a
tumour-specific signature in non-small cell lung cancer. Br J Cancer. 2013;
108:629–37. https://doi.org/10.1038/bjc.2012.567.
45. Pantulu ND, Pallasch CP, Kurz AK, Kassem A, Frenzel L, Sodenkamp S, Kvasnicka
HM, Wendtner CM, Zur Hausen A. Detection of a novel truncating Merkel cell
polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells.
Blood. 2010;116:5280–4. https://doi.org/10.1182/blood-2010-02-269829.
46. Velasquez C, Amako Y, Harold A, Toptan T, Chang Y, Shuda M.
Characterization of a Merkel cell Polyomavirus-positive Merkel cell
carcinoma cell line CVG-1. Front Microbiol. 2018;9:713. https://doi.org/10.
3389/fmicb.2018.00713.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Abdulsalam et al. Virology Journal           (2020) 17:54 Page 10 of 10
